PharmAla License Agreement and Share-Settlement Liability (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Aug. 20, 2026 |
Jul. 31, 2026 |
Jul. 20, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
May 19, 2026 |
Dec. 31, 2025 |
|
| Share settlement obligation amount | $ 1,833,333 | $ 1,833,333 | |||||||
| Cash obligation | 1,058,546 | ||||||||
| Equity consideration amount | $ 889,478 | 889,478 | |||||||
| Loss on fair value of license | (114,691) | (114,691) | |||||||
| Consideration payable | 1,058,546 | 1,058,546 | |||||||
| Pharm Ala Biotech Holdings Inc. [Member] | |||||||||
| Aggregate payment amount | $ 1,500,000 | ||||||||
| Share settlement obligation amount | 1,833,333 | 1,833,333 | |||||||
| Escrow deposit | $ 600,000 | ||||||||
| License agreements | $ 900,000 | ||||||||
| Cash consideration | 314,396 | 314,396 | |||||||
| Stock issued | 132,867 | ||||||||
| Outstanding shares | 181,529 | ||||||||
| Cash obligation | $ 1,058,546 | 1,058,546 | |||||||
| Equity consideration amount | $ 889,478 | 889,478 | |||||||
| Reset price per share | $ 5.8313 | ||||||||
| Loss on fair value of license | $ 114,691 | 114,691 | |||||||
| Consideration payable | $ 1,058,546 | $ 1,058,546 | |||||||
| X | ||||||||||
- Definition Aggregate payment amount. No definition available.
|
| X | ||||||||||
- Definition Noncash license consideration. No definition available.
|
| X | ||||||||||
- Definition Share settlement liability under license agreement. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Stock issued during period remaining shares. No definition available.
|
| X | ||||||||||
- Definition Shares issued under PharmAla license agreement. No definition available.
|
| X | ||||||||||
- Definition Amount of obligation incurred for right acquired by broadcaster under license agreement for program material, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|